Sunshine Guojian Pharmaceutical (Shanghai)'s weak ROE and ne...
Sunshine Guojian Pharmaceutical (Shanghai)'s weak ROE and net income decline may negatively affect the share price due to low earnings retention or inadequate capital allocation. Despite the industry's 11% growth over a 5-year period, the company's progress lags behind. Analysts predict a slight improvement in the company's earnings growth.
Can Mixed Fundamentals Have A Negative Impact on Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHSE:688336) Current Share Price Momentum?
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment